Medical Condition News

RSS

Latinos have higher rates of developing visual impairment than non-Hispanic whites: Researchers

Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease, and cataracts than non-Hispanic whites, researchers found. These are the first estimates of visual impairment and eye disease development in Latinos, the largest and fastest growing minority population in the United States.

3 May 2010

Vitamin E effective in treating NASH: Study

Vitamin E has been shown effective in treating nonalcoholic steatohepatitis, an obesity-associated chronic liver disease that can lead to cirrhosis, liver cancer, and death. NASH also is related to or a part of type 2 diabetes, lipid disorders and cardiovascular disease.

3 May 2010

New 4-D software program promises to improve treatment of lung cancer: Researchers

A new 4-dimensional software program promises to improve the treatment of lung cancer by allowing doctors to take the movement of breathing into account when administering radiotherapy, researchers announced today at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

30 Apr 2010

Accelerated radiotherapy improves overall survival of patient with NSCLC: Report

A new meta-analysis reported at the second European Lung Cancer Conference shows that patients with both non-small-cell lung cancer and small-cell lung cancer benefit in terms of overall survival when treated with hyperfractionated or accelerated radiotherapy.

30 Apr 2010

Kidney transplant recipients have higher risk of cancer: Researchers

Kidney transplant recipients are known to have a higher risk of cancer, compared to the general population, due to the need to take immunosuppressive drugs to prevent organ rejection. Results published today from a significant, long-term study suggest that no single medication appears to increase this cancer risk.

30 Apr 2010

Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound

Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model.

30 Apr 2010

Neuralstem's stem cell treatment for ALS featured on CNN with Dr. Sanjay Gupta

Neuralstem, Inc. announced that its stem cell treatment for ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease), currently in a FDA-approved Phase I clinical trial, was featured on CNN last night with Dr. Sanjay Gupta, in the piece entitled "Stem Cell Medical Breakthrough".

30 Apr 2010

Skin-colored hospital gowns can help detect cyanosis

Changing the hue of hospital gowns and bed sheets to match a patient's skin color could greatly enhance a physician's ability to detect cyanosis and other health-related skin color changes, according to a new study from Rensselaer Polytechnic Institute.

30 Apr 2010

Nuclear Pharm-Assist device for patients seeking care for cardiac, cancer diseases

Positron Corporation is a molecular imaging solutions company focused on Nuclear Cardiology states that its proprietary product line also includes unique solutions for the oncology community designed to enhance its position in this industry.

30 Apr 2010

UGA, Emory researchers awarded $1.9M grant to study role of regular exercise in attenuating drug abuse

A team of researchers at the University of Georgia and Emory University will receive $1.9 million over the next five years from the National Institutes of Health to study the neurobiological mechanisms for how regular aerobic exercise may prevent drug abuse relapse.

30 Apr 2010

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

Repligen Corporation announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder. The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.

30 Apr 2010

Researchers experiment different nanoparticles that may help surgeons remove glioblastomas

Researchers have developed a way to enhance how brain tumors appear in MRI scans and during surgery, making the tumors easier for surgeons to identify and remove.

30 Apr 2010

Short-term calorie restriction improves function of T-cells

Scientists funded by the Agricultural Research Service (ARS) found that volunteers who followed a low-calorie diet or a very low-calorie diet not only lost weight, but also significantly enhanced their immune response. The study may be the first to demonstrate the interaction between calorie restriction and immune markers among humans.

30 Apr 2010

IRIDEX commences commercial shipment of IQ 532 laser systems

IRIDEX Corporation, today announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.

30 Apr 2010

Researchers identify new genetic link to systemic scleroderma

An international research consortium including scientists from The University of Texas Health Science Center at Houston (UTHealth) has identified a new genetic link to the systemic form of scleroderma. Researchers believe a thorough understanding of the genetic nature of the disease is crucial to developing a cure.

30 Apr 2010

pSivida announces presentations on bioerodible technologies for degenerative eye disease

pSivida Corp., a leader in the development of back of the eye drug delivery systems, today announced that two poster presentations will be made at the upcoming ARVO meeting on one of pSivida's next generation bioerodible technologies for degenerative eye disease. It marks a key step toward the ability to use pSivida's bioerodible technologies to develop treatments for glaucoma and other degenerative eye diseases, diseases that affect millions of Americans.

30 Apr 2010

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.

30 Apr 2010

New PCA-Rx therapy provides natural toxin removal treatment to Alzheimer's patients

According to the Alzheimer's Association, over 5 million Americans are afflicted with Alzheimer's disease. While its cause is controversial, many people believe a correlation exists with toxin accumulation. Until recently, chelation, an invasive, drug-based toxin removal therapy, has been patients' primary option.

30 Apr 2010

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Acorda Therapeutics, Inc. today announced its financial results for the first quarter of 2010.

30 Apr 2010

Excess urinary protein excretion increases risk of kidney, heart complications in people with hypertension

Healthy people with high blood pressure who excrete a slight excess of protein in the urine raise their risk of developing kidney and heart complications. According to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN), more attention should focus on the potential health effects of urinary protein excretion in individuals with high blood pressure (hypertension).

30 Apr 2010

Medical Condition News

Latinos have higher rates of developing visual impairment than non-Hispanic whites: Researchers

Vitamin E effective in treating NASH: Study

New 4-D software program promises to improve treatment of lung cancer: Researchers

Accelerated radiotherapy improves overall survival of patient with NSCLC: Report

Kidney transplant recipients have higher risk of cancer: Researchers

Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound

Neuralstem's stem cell treatment for ALS featured on CNN with Dr. Sanjay Gupta

Skin-colored hospital gowns can help detect cyanosis

Nuclear Pharm-Assist device for patients seeking care for cardiac, cancer diseases

UGA, Emory researchers awarded $1.9M grant to study role of regular exercise in attenuating drug abuse

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

Researchers experiment different nanoparticles that may help surgeons remove glioblastomas

Short-term calorie restriction improves function of T-cells

IRIDEX commences commercial shipment of IQ 532 laser systems

Researchers identify new genetic link to systemic scleroderma

pSivida announces presentations on bioerodible technologies for degenerative eye disease

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

New PCA-Rx therapy provides natural toxin removal treatment to Alzheimer's patients

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Excess urinary protein excretion increases risk of kidney, heart complications in people with hypertension

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Latest News